Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn’s Disease.

Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn’s Disease. Inflamm Bowel Dis. 2018 Apr 13;: Authors: Waljee AK, Liu B, Sauder K, Zhu J, Govani SM, Stidham RW, Higgins PDR Abstract Background and Aims: Vedolizumab (VDZ) is effective for Crohn’s disease (CD) but costly and is slow to produce remission. Early knowledge of whether vedolizumab is likely to succeed is valuable for physicians, patients, and insurers. Methods: Phase 3 clinical trial data on VZD for CD were used to predict outcomes. Random forest modeling on the training cohort was used…

Read More

Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis.

Related Articles Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis. J Crohns Colitis. 2018 Apr 06;: Authors: Kevans D, Murthy S, Mould DR, Silverberg MS Abstract Background and Aims: A significant proportion of patients with corticosteroid-refractory acute ulcerative colitis [UC] fail therapy. We aimed to assess the pharmacokinetics [PK] of infliximab [IFX] in patients with corticosteroid-refractory acute UC and determine the association between induction IFX PK and short- and long-term therapy outcome. Methods: A population PK model was developed using data from…

Read More

Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn’s disease and ulcerative colitis exacerbation.

Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn’s disease and ulcerative colitis exacerbation. Aliment Pharmacol Ther. 2018 Apr 05;: Authors: Moninuola OO, Milligan W, Lochhead P, Khalili H Abstract BACKGROUND: Unlike acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs) have generally been thought to be associated with increased risk of IBD exacerbation. AIM: To carry out a systematic review and meta-analysis of previous studies examining the association between acetaminophen and NSAIDs including cyclooxygenase (COX-2) inhibitors use, and risk of Crohn’s disease (CD) and ulcerative colitis…

Read More

A proposed treatment algorithm for mild to moderate ulcerative colitis-with an emphasis on budesonide foam and mucosal healing.

Related Articles A proposed treatment algorithm for mild to moderate ulcerative colitis-with an emphasis on budesonide foam and mucosal healing. J Gastroenterol. 2018 Apr 03;: Authors: Pokrotnieks J, Sitkin S PMID: 29616331 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29616331?dopt=Abstract

Read More

Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinician.

Related Articles Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinician. J Gastroenterol Hepatol. 2018 Mar 30;: Authors: Miehlke S, Acosta MB, Bouma G, Carpio D, Magro F, Moreels T, Probert C Abstract Oral budesonide is a second- generation steroid which allows local, selective treatment of the gastrointestinal tract and the liver, minimizing systemic exposure. The results of randomized trials comparing budesonide versus placebo or active comparators have led to expert recommendations that budesonide be used to treat mild or moderate active ileocecal Crohn’s disease, microscopic…

Read More

Past Time for Doctors to Lessen their Dependence on Corticosteroids in the Treatment of IBD.

Past Time for Doctors to Lessen their Dependence on Corticosteroids in the Treatment of IBD. Am J Gastroenterol. 2018 Mar;113(3):418-420 Authors: Bernstein CN Abstract Corticosteroids and antibodies to tumor necrosis factor (anti-TNF) are mainstays of treatment of acutely active IBD and while anti-TNF therapy is indicated for maintenance therapy, chronic corticosteroid therapy is associated with known significant risks. Nonetheless, chronic or recurrent corticosteroid treatment in IBD is common. In this edition of the journal Lewis et al. use Medicaid and Medicare databases to contrast adverse outcomes in persons with IBD…

Read More

“Addition of granulocyte/monocyte apheresis to oral prednisone for steroid-dependent ulcerative colitis: A randomized, multicentre, clinical trial”.

“Addition of granulocyte/monocyte apheresis to oral prednisone for steroid-dependent ulcerative colitis: A randomized, multicentre, clinical trial”. J Crohns Colitis. 2018 Feb 27;: Authors: Domènech E, Panés J, Hinojosa J, Annese V, Magro F, Sturniolo GC, Bossa F, Fernández F, González-Conde B, García-Sánchez V, Dignass A, Manuel Herrera J, Cabriada JL, Guardiola J, Vecchi M, Portela F, Ginard D, ATTICA Study Group* by the Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa. Abstract Background and Aims: Steroid-dependency occurs in up to 30% of patients with ulcerative colitis (UC).…

Read More

Safety and efficacy of leukocytapheresis in elderly patients with ulcerative colitis: the impact in steroid-free elderly patients.

Safety and efficacy of leukocytapheresis in elderly patients with ulcerative colitis: the impact in steroid-free elderly patients. J Gastroenterol Hepatol. 2018 Feb 06;: Authors: Komoto S, Matsuoka K, Kobayashi T, Yokoyama Y, Suzuki Y, Hibi T, Miura S, Hokari R Abstract BACKGROUND: The number of elderly patients with ulcerative colitis (UC) is increasing. Several new therapies for UC have improved patient outcomes. Leukocytapheresis (LCAP) is an extracorporeal therapy for UC. However, its efficacy and safety for elderly UC patients has not been reported. METHODS: We conducted a post hoc analysis…

Read More

Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitis.

Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitis. Aliment Pharmacol Ther. 2018 Jan 22;: Authors: Waljee AK, Liu B, Sauder K, Zhu J, Govani SM, Stidham RW, Higgins PDR Abstract BACKGROUND: Vedolizumab is an effective therapy for ulcerative colitis (UC), but costly and slow to work. New clinical responses occur after 30 weeks of therapy. AIMS: To enable physicians, patients, and insurers to predict whether a patient with UC will respond to vedolizumab at an early time point after starting therapy. METHODS: The clinical study data request website provided the…

Read More

Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease.

Related Articles Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease. Am J Gastroenterol. 2018 Jan 16;: Authors: Lewis JD, Scott FI, Brensinger CM, Roy JA, Osterman MT, Mamtani R, Bewtra M, Chen L, Yun H, Xie F, Curtis JR Abstract OBJECTIVES: Crohn’s disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) that compromise quality of life and may increase mortality. This study compared the mortality risk with prolonged corticosteroid use vs. antitumor necrosis factor-α (anti-TNF) drugs in IBD.…

Read More
<< Go Back